Thomas E. Hutson, DO, PharmD

Personal advice on how to manage living with RCC.

Experts share future perspectives on the treatment and management of patients with RCC.

A patient's perspective on managing the side effects of treatment for advanced RCC.

Dr. Hutson explains approaches to educating patients on potential side effects of immunotherapy combinations for kidney cancer, empowering them to manage side effects and maintain quality of life while getting clinical benefit from these life-extending therapies.

Kidney cancer, which once had few treatment options, now has multiple oral targeted therapies leading to improved survival; immunotherapy combinations further increased clinical benefit over previous options, providing clinicians several approved regimens from which to choose the optimal therapy for each patient.

Mr. Fuentes felt it was important to understand the range of potential side effects to anticipate how his body would potentially react to treatment for RCC and determine his physical abilities and support needs, but was most focused on whether his first post-treatment scan showed tumor shrinkage.

Nurses play a key role in kidney cancer care by educating patients on medications, closely monitoring and managing side effects, coordinating care, providing emotional support, and serving as the first line of communication with patients about treatment concerns.

After his initial fear, Mr. Fuentes educated himself extensively on cancer to understand his diagnosis, which along with having a treatment plan in place, specialist referrals, and tolerable side effects, helps him maintain a positive mindset and manageable quality of life with stage 4 disease.

Mr. Cesar Fuentes had a kidney tumor surgically removed; lymph node and bone metastases years later led to immune and targeted therapy which have provided significant tumor shrinkage and generally mild, manageable side effects.

Dr Thomas Hutson outlines the diagnosis and staging of renal cell carcinoma, the surgical and non-surgical treatment options, and notes that while the majority of cases are potentially curable, 20-25% of patients present with or later develop metastatic disease.

Thomas Hutson, DO, PharmD, discusses renal cell carcinoma, including its epidemiology, risk factors, subtypes, and management approaches, in a dialogue with his clinical nurse, Kacie Ellis, RN, and his patient, Mr. Cesar Fuentes.

Drs Thomas Hutson and Scott Tykodi explain when to consider a debulking surgery for patients with renal cell carcinoma.

A look at how to best sequence therapies for renal cell carcinoma from the front-line setting on.

Thought leaders explain how they dose IO/TKI treatment regimens to better manage side effects in patients with renal cell carcinoma.

Dr Scott Tykodi provides advice for community oncologists managing patients with renal cell carcinoma.

Thomas Hutson, DO, PharmD, and Scott Tykodi, MD, PhD, discuss their takeaways from the CLEAR trial and how risk category stratification affected the study.

Oncologists debate whether TKI monotherapy has a place in renal cell carcinoma treatment after the CLEAR trial.